Dermata Therapeutics Inc (NASDAQ: DRMA)’s stock price has gone rise by 9.48 in comparison to its previous close of 1.33, however, the company has experienced a 8.66% increase in its stock price over the last five trading days. accesswire.com reported 2024-10-08 that SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the Company’s CEO, Gerry Proehl, will present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15, 2024, at 3:30PM ET. Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management.
Is It Worth Investing in Dermata Therapeutics Inc (NASDAQ: DRMA) Right Now?
Moreover, the 36-month beta value for DRMA is 0.77. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DRMA is 1.48M and currently, short sellers hold a 4.67% of that float. On October 17, 2024, DRMA’s average trading volume was 2.52M shares.
DRMA’s Market Performance
DRMA stock saw a decrease of 8.66% in the past week, with a monthly decline of -35.28% and a quarterly a decrease of -15.60%. The volatility ratio for the week is 10.08%, and the volatility levels for the last 30 days are 10.47% for Dermata Therapeutics Inc (DRMA). The simple moving average for the last 20 days is -0.20% for DRMA’s stock, with a simple moving average of -64.91% for the last 200 days.
DRMA Trading at -15.12% from the 50-Day Moving Average
After a stumble in the market that brought DRMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.04% of loss for the given period.
Volatility was left at 10.47%, however, over the last 30 days, the volatility rate increased by 10.08%, as shares sank -20.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.91% lower at present.
During the last 5 trading sessions, DRMA rose by +4.48%, which changed the moving average for the period of 200-days by -84.18% in comparison to the 20-day moving average, which settled at $1.4562. In addition, Dermata Therapeutics Inc saw -84.09% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for DRMA
The total capital return value is set at -3.05. Equity return is now at value -173.01, with -140.74 for asset returns.
Currently, EBITDA for the company is 0.25 million with net debt to EBITDA at 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.73.
Conclusion
To wrap up, the performance of Dermata Therapeutics Inc (DRMA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
